These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22525969)

  • 41. Sample size estimation using a latent variable model for mixed outcome co-primary, multiple primary and composite endpoints.
    McMenamin ME; Barrett JK; Berglind A; Wason JMS
    Stat Med; 2022 Jun; 41(13):2303-2316. PubMed ID: 35199380
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Power and sample size considerations in clinical trials with competing risk endpoints.
    Maki E
    Pharm Stat; 2006; 5(3):159-71. PubMed ID: 17080750
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Introducing a new estimator and test for the weighted all-cause hazard ratio.
    Ozga AK; Rauch G
    BMC Med Res Methodol; 2019 Jun; 19(1):118. PubMed ID: 31185922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Statistical tests based on new composite hypotheses in clinical trials reflecting the relative clinical importance of multiple endpoints quantitatively.
    Nishikawa M; Tango T; Ohtaki M
    Biom J; 2009 Oct; 51(5):749-62. PubMed ID: 19777463
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sample size determination and re-estimation for matched pair designs with multiple binary endpoints.
    Xu J; Yu M
    Biom J; 2013 May; 55(3):430-43. PubMed ID: 23553605
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reducing unnecessary measurements in clinical trials with multiple primary endpoints.
    Sozu T; Sugimoto T; Hamasaki T
    J Biopharm Stat; 2016; 26(4):631-43. PubMed ID: 26098617
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Some comments on frequently used multiple endpoint adjustment methods in clinical trials.
    Sankoh AJ; Huque MF; Dubey SD
    Stat Med; 1997 Nov; 16(22):2529-42. PubMed ID: 9403954
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Power and sample size determination in clinical trials with multiple primary continuous correlated endpoints.
    Lafaye de Micheaux P; Liquet B; Marque S; Riou J
    J Biopharm Stat; 2014; 24(2):378-97. PubMed ID: 24605975
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Time-to-first-event versus recurrent-event analysis: points to consider for selecting a meaningful analysis strategy in clinical trials with composite endpoints.
    Rauch G; Kieser M; Binder H; Bayes-Genis A; Jahn-Eimermacher A
    Clin Res Cardiol; 2018 May; 107(5):437-443. PubMed ID: 29453594
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis.
    Chen YH; DeMets DL; Lan KK
    Control Clin Trials; 2003 Feb; 24(1):16-27. PubMed ID: 12559639
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A systematic comparison of recurrent event models for application to composite endpoints.
    Ozga AK; Kieser M; Rauch G
    BMC Med Res Methodol; 2018 Jan; 18(1):2. PubMed ID: 29301487
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Method of balanced adjustment in testing co-primary endpoints.
    Kordzakhia G; Siddiqui O; Huque MF
    Stat Med; 2010 Aug; 29(19):2055-66. PubMed ID: 20683896
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improving the analysis of composite endpoints in rare disease trials.
    McMenamin M; Berglind A; Wason JMS
    Orphanet J Rare Dis; 2018 May; 13(1):81. PubMed ID: 29788976
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessing the impact of endpoint shopping on power in confirmatory clinical trials.
    Wiens BL
    J Biopharm Stat; 2003 May; 13(2):229-40. PubMed ID: 12729391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging standards in statistical practice: implications for clinical trials in rehabilitation medicine.
    Millis SR
    Am J Phys Med Rehabil; 2003 Oct; 82(10 Suppl):S32-7. PubMed ID: 14502037
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A note on testing families of hypotheses using graphical procedures.
    Maurer W; Bretz F
    Stat Med; 2014 Dec; 33(30):5340-6. PubMed ID: 25043831
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design and analysis issues of multiregional clinical trials with different regional primary endpoints.
    Tsou HH; Tsong Y; Chang WJ; Dong X; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):1051-9. PubMed ID: 22946949
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Some controversial multiple testing problems in regulatory applications.
    Hung HM; Wang SJ
    J Biopharm Stat; 2009; 19(1):1-11; discussion 12-41. PubMed ID: 19127460
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A power study of a sequential method of p-value adjustment for correlated continuous endpoints.
    Arani RB; Chen JJ
    J Biopharm Stat; 1998 Nov; 8(4):585-98. PubMed ID: 9855036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.